Moreover, AR can induce DSB repair in prostate cancer cells [53], which prompted us to move on to a combination treatment with a PARP inhibitor and androgen receptor signaling inhibitors (ARSIs) for patients with CRPC. The gene discussed is PARP1; the disease is prostate cancer.